GYRE THERAPEUTICS, INC.

Annual Trend FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 TTM
Cash flows from operating activities:
Adjustments to reconcile net income to net cash provided by operating activities:
Net Income (Loss) Available to Common Stockholders, Basic ($25.5m)
($30.1m) -17.81%
($55.2m) -83.59%
($56.2m) -1.93%
($92.9m)
$12.1m +113.00%
$5.0m -58.40%
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest ($16.9m) ($21.6m) ($30.1m) ($55.2m) ($56.2m) ($87.9m) ($8.2m) ($85.5m) $17.9m $9.9m
Net Income (Loss) Attributable to Noncontrolling Interest $7.5m $5.8m $4.9m
Depreciation, Depletion and Amortization $389k $173k $149k $146k $138k $290k $230k $1.1m $1.5m $2.5m $3.1m
Depreciation $400k $200k $100k $146k $138k $290k $230k $1.0m $1.3m $2.0m $3.1m
Amortization of Debt Issuance Costs $9k
Amortization of Intangible Assets $100k $38k $576k
Amortization of land use rights $42k $40k $39k $39k
Deferred Income Tax Expense (Benefit) ($834k) ($1.0m) ($1.1m) ($2.8m)
Deferred income taxes, net ($838k) ($1.2m) ($1.0m) ($1.1m) ($2.8m)
Share-based Payment Arrangement, Noncash Expense $635k $863k $2.6m $3.2m $3.6m $3.4m $1.3m $7.3m $831k $7.2m $9.9m
Share-based Payment Arrangement, Expense $635k $863k $2.6m $3.2m $3.6m $3.4m $1.3m $7.3m $831k $7.2m $9.9m
Stock-based compensation $635k $863k $2.6m $3.2m $3.6m $3.4m $1.3m $7.3m $831k $7.2m $9.9m
Equity Method Investment, Other than Temporary Impairment ($1.3m) ($1.0m) $0 $0
Other Nonoperating Income (Expense) $86k $261k $1.6m ($39k) $659k ($87k) ($1.7m) ($1.5m)
Purchase of equity method investment ($1.3m) ($1.0m) ($1.7m)
Changes in operating assets and liabilities:
Increase (Decrease) in Accounts Receivable ($461k) ($7k) $15.0m ($11.7m) ($1.5m) $5.3m $10.8m ($1.4m)
Change in fair value of receivables from GCBP ($39k) $239k ($39k)
Accounts receivable $461k $7k ($15.0m) $11.7m $1.5m $285k ($5.3m) ($10.8m) ($1.4m)
Increase (Decrease) in Inventories ($1.7m) $2.1m $3.6m ($2.1m)
Inventories ($879k) $1.7m ($2.1m) ($3.6m) ($2.1m)
Increase (Decrease) in Accounts Payable ($102k) ($90k) $500k $3.0m $1.7m $500k ($6.2m) $192k ($245k) $13k ($551k)
Accrued interest on bank deposit ($633k) ($1.0m) $28k
Accrued expenses and other liabilities $1.9m $1.4m ($1.5m) $946k
Prepaid and other assets $956k ($351k) ($2.9m) ($490k) ($3.0m) $3.9m $1.6m ($82k) $520k ($206k)
Net Cash Provided by (Used in) Operating Activities ($18.5m)
($19.9m) -7.95%
($28.6m) -43.19%
($43.6m) -52.74%
($55.0m) -26.22%
($83.8m) -52.15%
($33.1m) +60.48%
$25.9m +178.23%
($3.6m) -114.06%
$1.0m +127.74%
($4.9m) -588.61%
Cash flows from investing activities:
Payments to Acquire Property, Plant, and Equipment $468k $23k $376k $64k ($267k) ($839k) $727k $8.5m $2.3m $1.2m ($2.2m)
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property $600k $0 ($116k) $498k $628k $66k $4k ($319k)
Gain (Loss) on Disposition of Property Plant Equipment $557k $0 ($116k) $498k ($628k) ($66k) ($4k) ($319k)
Proceeds from sale of equipment $1.7m $664k $401k $30k
Cash, Cash Equivalents, and Short-term Investments $17.1m $32.4m $120.1m $76.9m $81.9m $46.9m $21.7m $33.5m
Debt Securities, Available-for-sale, Realized Gain (Loss) $0
Payments to Acquire Investments $13.4m $25.5m $267k $839k ($1.5m)
Net Cash Provided by (Used in) Investing Activities ($11.2m) ($71.3m) $27.4m $9.7m $48.2m $55.4m ($19.8m) ($19.9m) ($474k) $2.9m
Cash flows from financing activities:
Gain (Loss) on Extinguishment of Debt $99k $0
Bad debt expense and other non-cash items $22k ($61k) $170k ($63k)
Proceeds from Issuance of Common Stock $958k $5.3m $773k $23.5m $0
Proceeds from the issuance of common stock $958k $5.3m $106.8m $773k $23.5m
Dividends paid $45
Dividends Payable, Current $8
Net Cash Provided by (Used in) Financing Activities $21.1m
$111.3m +428.09%
$327k -99.71%
$60.4m +18363.61%
$49.6m -17.93%
($45.0m) -190.83%
$2.5m +105.55%
$2.1m -15.92%
$24.4m +1059.75%
$2.8m -88.51%
Net increase (decrease) in cash and cash equivalents ($18.8m) $4.2m $11.5m ($15.9m) $15.0m $14.0m ($22.7m) $8.3m ($21.7m) $25.3m
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $11.5m ($15.9m) $15.0m $14.0m ($22.7m) $8.3m ($21.7m) $25.3m $57.1m
Cash and cash equivalents at beginning of the period $19.8m $31.3m $15.4m $30.4m $44.3m $21.7m $33.5m $11.8m $37.1m
Effect of exchange rate changes on cash and cash equivalents ($1.9m) ($298k) ($273k) $343k $1.3m
Additional Supplementary Disclosures
Additional Supplementary Disclosures
Proceeds from Stock Options Exercised $0 $1.9m $2.4m
Supplemental disclosure of cash flow information:
Income Taxes Paid, Net $6.3m $6.3m $8.5m $5.6m
Additional Financial Items
Derivative, Gain (Loss) on Derivative, Net $1.1m
Gain (Loss) on Disposition of Assets $1.7m ($18k) $57.2m ($4k)
Gain (Loss) on Disposition of Business ($2.7m)
General and Administrative Expense $9.3m $10.0m $12.4m $13.4m $16.2m $19.0m $17.4m $14.7m $16.1m $20.8m
Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest ($85.5m) $17.9m $9.9m
Income Tax Expense (Benefit) $348k $8.5m $5.3m $4.6m
Operating Expenses $20.8m $22.8m $33.8m $57.3m $78.3m $95.2m $9.4m $176.0m $85.7m $105.1m
Operating Lease, Expense $600k $700k $1.7m $1.7m $500k $700k $900k
Payments of Financing Costs $1.5m
Revenue from Contract with Customer, Including Assessed Tax $113.5m $105.8m
Noncash lease expense $404k $355k $672k $777k
Change in fair value of derivative liabilities $39k $239k $39k
Change in fair value of warrant liability $9.3m ($7.2m) ($2.7m)
Equity loss of unconsolidated affiliates $251k $1.3m $37k $77k
Notes receivable $1.1m ($4.0m) ($1.1m)
Income tax payable ($1.3m) $3.0m ($2.2m) $44k
Other noncurrent liabilities ($102k) $23k ($47k)
Due to related parties $425k ($83k) ($1k)
Operating lease liabilities ($429k) ($473k) ($816k) ($744k)
Acquisition of intangible assets ($13k) ($69k) ($813k) ($733k)
Purchase of certificates of deposit ($7.5m) ($15.7m) ($15.5m) ($14.0m)
Offering costs paid ($536k) ($1.5m)
Proceeds from the exercise of stock options $0 $1.9m $2.4m
Right-of-use asset obtained in exchange for operating lease liabilities $57k $277k $2.0m $63k